These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 23078638

  • 1. Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
    Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.
    Diabetes Obes Metab; 2013 Mar; 15(3):264-71. PubMed ID: 23078638
    [Abstract] [Full Text] [Related]

  • 2. Evolution of exenatide as a diabetes therapeutic.
    Bhavsar S, Mudaliar S, Cherrington A.
    Curr Diabetes Rev; 2013 Mar 01; 9(2):161-93. PubMed ID: 23256660
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.
    Postgrad Med; 2013 May 01; 125(3):47-57. PubMed ID: 23748506
    [Abstract] [Full Text] [Related]

  • 4. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
    Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B.
    Vasc Health Risk Manag; 2012 May 01; 8():255-64. PubMed ID: 22566747
    [Abstract] [Full Text] [Related]

  • 5. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA, Boye KS, Timlin L, Clark JF, Best JH.
    Diabetes Obes Metab; 2013 Mar 01; 15(3):213-23. PubMed ID: 22958381
    [Abstract] [Full Text] [Related]

  • 6. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L.
    J Clin Endocrinol Metab; 2011 May 01; 96(5):1301-10. PubMed ID: 21307137
    [Abstract] [Full Text] [Related]

  • 7. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.
    Clin Ther; 2007 Jan 01; 29(1):139-53. PubMed ID: 17379054
    [Abstract] [Full Text] [Related]

  • 8. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J, Dotta F, Festa A, Zhou M, Kiljański J.
    Cardiovasc Diabetol; 2015 Sep 04; 14():116. PubMed ID: 26338040
    [Abstract] [Full Text] [Related]

  • 9. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR, DeYoung MB, Han J, Best JH, Grimm M.
    Cardiovasc Diabetol; 2013 Mar 23; 12():48. PubMed ID: 23522121
    [Abstract] [Full Text] [Related]

  • 10. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.
    Diabetes Obes Metab; 2012 Dec 23; 14(12):1097-103. PubMed ID: 22734440
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J, Meloni A, Han J.
    Postgrad Med; 2013 May 23; 125(3):58-67. PubMed ID: 23748507
    [Abstract] [Full Text] [Related]

  • 12. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
    Blonde L, Pencek R, MacConell L.
    Cardiovasc Diabetol; 2015 Feb 03; 14():12. PubMed ID: 25645567
    [Abstract] [Full Text] [Related]

  • 13. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.
    Diabet Med; 2011 Jun 03; 28(6):705-14. PubMed ID: 21434995
    [Abstract] [Full Text] [Related]

  • 14. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.
    Diabetes Obes Metab; 2015 Jul 03; 17(7):689-98. PubMed ID: 25846577
    [Abstract] [Full Text] [Related]

  • 15. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
    Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.
    Curr Med Res Opin; 2008 Jan 03; 24(1):275-86. PubMed ID: 18053320
    [Abstract] [Full Text] [Related]

  • 16. Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.
    Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A.
    Int J Clin Pract; 2018 Mar 03; 72(3):e13055. PubMed ID: 29341370
    [Abstract] [Full Text] [Related]

  • 17. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M.
    Diabetes Obes Metab; 2015 Feb 03; 17(2):145-51. PubMed ID: 25323312
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan 03; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2017 Apr 03; 19(4):524-536. PubMed ID: 27981757
    [Abstract] [Full Text] [Related]

  • 20. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA.
    Lancet Diabetes Endocrinol; 2016 Dec 03; 4(12):1004-1016. PubMed ID: 27651331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.